Enhertu achieved statistically significant overall survival
AstraZeneca and Daiichi Sankyo’s Enhertu also improved progression-free survival by 22 months vs.T-DM1 in patients previously treated with HER2-directed therapy in the DESTINY-Breast03 Phase III trial. Enhertu showed significant progression-free and overall survival improvements vs. chemotherapy in later-line HER2-positive setting in the DESTINY-Breast02 Phase III trial.Updated results from the DESTINY-Breast03 Phase III trial showed that Enhertu (trastuzumab deruxtecan) demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) compared to